Arcturus Therapeutics Valuation
| ARCT Stock | USD 7.51 0.11 1.49% |
At this time, the firm appears to be undervalued. Arcturus Therapeutics shows a prevailing Real Value of $7.95 per share. The current price of the firm is $7.51. Our model approximates the value of Arcturus Therapeutics from analyzing the firm fundamentals such as profit margin of (0.68) %, and Return On Equity of -0.27 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Arcturus Therapeutics' valuation include:
Price Book 0.9363 | Enterprise Value | Enterprise Value Ebitda (25.67) | Price Sales 2.1864 | Forward PE 2.4777 |
Undervalued
Today
Please note that Arcturus Therapeutics' price fluctuation is slightly risky at this time. Calculation of the real value of Arcturus Therapeutics is based on 3 months time horizon. Increasing Arcturus Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Arcturus Therapeutics' intrinsic value may or may not be the same as its current market price of 7.51, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 7.51 | Real 7.95 | Target 33.56 | Hype 7.51 | Naive 7.36 |
The intrinsic value of Arcturus Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Arcturus Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Arcturus Therapeutics Holdings helps investors to forecast how Arcturus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Arcturus Therapeutics more accurately as focusing exclusively on Arcturus Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Arcturus Therapeutics' intrinsic value based on its ongoing forecasts of Arcturus Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Arcturus Therapeutics' closest peers.
Arcturus Therapeutics Cash |
|
Arcturus Revenue by Product
Arcturus Therapeutics Total Value Analysis
Arcturus Therapeutics Holdings is presently forecasted to have valuation of 55.89 M with market capitalization of 213.39 M, debt of 28.55 M, and cash on hands of 283.49 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Arcturus Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
55.89 M | 213.39 M | 28.55 M | 283.49 M |
Arcturus Therapeutics Investor Information
About 78.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.94. Some equities with similar Price to Book (P/B) outperform the market in the long run. Arcturus Therapeutics has Price/Earnings (P/E) ratio of 119.5. The entity recorded a loss per share of 2.5. The firm last dividend was issued on the 16th of November 2017. Arcturus Therapeutics had 1:7 split on the 16th of November 2017. Based on the key indicators related to Arcturus Therapeutics' liquidity, profitability, solvency, and operating efficiency, Arcturus Therapeutics Holdings may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Arcturus Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Arcturus Therapeutics has an asset utilization ratio of 40.22 percent. This implies that the Company is making $0.4 for each dollar of assets. An increasing asset utilization means that Arcturus Therapeutics Holdings is more efficient with each dollar of assets it utilizes for everyday operations.Arcturus Therapeutics Profitability Analysis
Based on Arcturus Therapeutics' profitability indicators, Arcturus Therapeutics Holdings may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Arcturus Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2012-06-30 | Previous Quarter -9.2 M | Current Value -13.4 M | Quarterly Volatility 25.2 M |
For Arcturus Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Arcturus Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Arcturus Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Arcturus Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Arcturus Therapeutics over time as well as its relative position and ranking within its peers.
Arcturus Therapeutics Earnings per Share Projection vs Actual
The next projected EPS of Arcturus Therapeutics is estimated to be -0.6075 with future projections ranging from a low of -1.15 to a high of 0.08. Arcturus Therapeutics' most recent 12-month trailing earnings per share (EPS TTM) is at -2.5. Please be aware that the consensus of earnings estimates for Arcturus Therapeutics Holdings is based on EPS before non-recurring items and includes expenses related to employee stock options.Arcturus Therapeutics Earnings Estimation Breakdown
The calculation of Arcturus Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Arcturus Therapeutics is estimated to be -0.6075 with the future projection ranging from a low of -1.15 to a high of 0.08. Please be aware that this consensus of annual earnings estimates for Arcturus Therapeutics Holdings is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-1.15 Lowest | Expected EPS | 0.08 Highest |
Arcturus Therapeutics Earnings Projection Consensus
Suppose the current estimates of Arcturus Therapeutics' value are higher than the current market price of the Arcturus Therapeutics stock. In this case, investors may conclude that Arcturus Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Arcturus Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 12 | 19.66% | 0.0 | -0.6075 | -2.5 |
Arcturus Therapeutics Ownership Allocation
Arcturus Therapeutics holds a total of 28.41 Million outstanding shares. The majority of Arcturus Therapeutics Holdings outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Arcturus Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Arcturus Therapeutics. Please pay attention to any change in the institutional holdings of Arcturus Therapeutics Holdings as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Arcturus Therapeutics Profitability Analysis
The company reported the previous year's revenue of 138.39 M. Net Loss for the year was (80.94 M) with loss before overhead, payroll, taxes, and interest of (94.39 M).About Arcturus Therapeutics Valuation
The stock valuation mechanism determines Arcturus Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Arcturus Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Arcturus Therapeutics. We calculate exposure to Arcturus Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Arcturus Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 159.1 M | 167.1 M | |
| Pretax Profit Margin | (0.67) | (0.71) | |
| Operating Profit Margin | (0.80) | (0.83) | |
| Net Loss | (0.67) | (0.71) | |
| Gross Profit Margin | (5.59) | (5.31) |
Arcturus Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Arcturus Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 27 M | |
| Forward Price Earnings | 2.4777 |
Arcturus Therapeutics Current Valuation Indicators
Arcturus Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Arcturus Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Arcturus Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Arcturus Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Arcturus Therapeutics' worth.Additional Tools for Arcturus Stock Analysis
When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.